anti-CD20-IgG1-huEndoP125A (Synergys Biotherapeutics/University of Miami Miller School of Medicine)

N/A

Report date: 2025/03/14 16:25:05

Base Information

Drug Nameanti-CD20-IgG1-huEndoP125A (Synergys Biotherapeutics/University of Miami Miller School of Medicine)
Drug Alias Nameanti-CD20 endostatin fusion protein (Synergys Biotherapeutics/University of Miami Miller School of Medicine)antibody fusion protein (Synergys Biotherapeutics/University of Miami Miller School of Medicine)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsEndostatin modulators
TargetsB-lymphocyte antigen CD20Endostatin
Therapy Area/IndicationsLymphoma, Mantle-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of Miami Miller School of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesSynergys Biotherapeutics IncUniversity of Miami Miller School of Medicine
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A